Rapport Therapeutics, Inc. RAPP
Rapport Therapeutics, Inc. (Nasdaq: RAPP) is a CNS/neurology/psychiatry drug developer. Its lead program, RAP-219, is in Phase 3 for drug-resistant focal onset seizures. Its next catalyst on record is RAP-219: FDA meeting planned Q1 2027 on bipolar mania registrational design; two Phase 3 trials expected to begin 2H 2027. (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: RAP-219 — FDA meeting planned Q1 2027 on bipolar mania registrational design; two Phase 3 trials expected to begin 2H 2027. (H2 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| RAP-219 | focal onset seizures | small molecule | Phase 3 |
| RAP-219 | PGTCS | small molecule | Phase 3 |
| RAP-219 | bipolar mania | small molecule | Phase 2 |
| RAP-219 LAI | epilepsy | small molecule | Phase 1 |
| RAP-641 | CNS | small molecule | Pre-clinical |
| alpha9alpha10 nAChR | pain | small molecule | Pre-clinical |
Recent results and decisions
- Oct 20, 2026met Randomized Phase 2 (n=253) met primary endpoint: 3.1-point placebo-adjusted YMRS improvement at Week 3 (15.4 vs 12.3 points, p=0.045); CGI-BP-S secondary also met (0.4, p=0.024); well tolerated.
The trial met its primary endpoint, with RAP-219 achieving a 3.1-point placebo-adjusted improvement in the Young Mania Rating Scale (YMRS) total score at Week 3
Filing - Aug 5, 2026started Phase 3 program in FOS initiated in Q2 2026 with two parallel trials, FOCUS 1 and FOCUS 2, now enrolling patients.
The Company initiated its Phase 3 program in FOS in the second quarter of 2026, with two parallel trials—FOCUS 1 and FOCUS 2—enrolling patients.
Filing - Aug 5, 2026approval China NMPA (ex-US regulator) approved the IND for RAP-219 Phase 3 trials in FOS; Tenacia expects China recruitment to begin in 4Q 2026.
China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for RAP-219 Phase 3 trials in FOS; Tenacia expects patient recruitment in China to begin in 4Q 2026.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.